Hormona is more than a product — it’s a movement and a direct answer to the decades-long silence and stigma surrounding women’s hormonal health. Founded by women, for women, Hormona is unlocking access to personalized hormone tracking with lab-level accuracy — without the barriers, wait times, or guesswork that have long defined women’s healthcare.
“We invest in the impossible — and Hormona is doing what once seemed impossible: giving millions of women control over their own biology through tech, data, and relentless empathy,” says Inka Mero, Founder and Managing Partner at Voima Ventures. “They are not just building a company — they are redefining what healthcare means for half the population.”
Hormona’s oversubscribed $6.7M Seed round was co-led by Supernode VC (London), with participation from DLF Ventures (Brussels), Nascent Invest (Sweden), and Techstars (US). The funding will power the global launch of Hormona’s first-of-its-kind quantitative hormone tests, expand B2B partnerships, and accelerate the platform’s technology, reach, and impact.
Hormona: Technology with Purpose
Hormona’s mission is deeply personal. CEO and co-founder Karolina Löfqvist spent years suffering from hormone-related symptoms without a clear diagnosis — a reality shared by 80% of women worldwide. That experience fueled the company’s creation: a science-backed solution to help women take control of their hormonal health.
“For too long, women have had to suffer through hormonal issues, relying on trial and error and waiting until symptoms become unbearable. That’s no way to live,” Löfqvist says. “We built Hormona to change that — to make real-time hormone tracking accessible, without the need for repeated blood draws. This investment brings us one step closer to that future.”
Hormona combines AI-powered insights with at-home hormone testing to help women detect imbalances, track fluctuations, and better manage conditions like PCOS, irregular cycles, and perimenopause. The company’s proprietary testing tech is over 90% accurate compared to venous blood sampling, while offering continuous, affordable tracking — eliminating the need for clinical labs.
Why Voima Ventures Invested in Hormona
Hormona is already a leader in femtech — and with the support of science-driven investors like us, they’re scaling into a category of their own.
The Future Is Personalized, Predictive, and Female-Led
This investment aligns with Voima Ventures’ core thesis: to back scientifically validated, user-centric solutions solving systemic health challenges, also for women. Voima Ventures believes that the future of healthcare lies at the intersection of data, empathy, and inclusivity.
